Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2026
Phenotype and prognosis of primary sclerosing cholangitis-autoimmune hepatitis variant syndrome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kolev Mirjam, Bütikofer Rahel, Krucker Yasemin, Soret Pierre-Antoine, Wendum Dominique, Arrivé Lionel, Wagner Mathilde, Chazouillères Olivier, Corpechot Christophe, Lemoinne Sara
Аннотация
BACKGROUND AND AIMS: A subset of patients with primary sclerosing cholangitis (PSC) exhibits features of autoimmune hepatitis (AIH), referred to as PSC-AIH variant syndrome (VS). Data on the phenotype and prognosis of VS remain limited. We compared clinical characteristics and outcomes of patients with VS and PSC without VS (non-VS).
METHODS: This retrospective cohort study included patients with PSC followed at a tertiary referral center. VS was defined as moderate-to-severe interface hepatitis on liver histology combined with at least one of the following: alanine aminotransferase ≥5 × upper limit of normal (ULN), IgG ≥1.5 × ULN, or smooth muscle antibody titer ≥1:80.
RESULTS: Twenty-eight patients with VS and 274 non-VS patients were included. At diagnosis, VS patients were younger (median 20 vs. 30 years, p < 0.001), less frequently had inflammatory bowel disease (46.4% vs. 77.7%, p = 0.001), and more often presented with cirrhosis (25% vs. 8%, p = 0.010). Median follow-up was 9.9 years. Adjusted transplant-free survival was similar between groups (HR 0.33, 95% CI 0.11-1.00; p = 0.051). After adjustment, VS was associated with a lower risk of liver-related events (HR 0.27, 95% CI 0.09-0.80; p = 0.019).
CONCLUSIONS: Despite more frequent cirrhosis at diagnosis, patients with VS had comparable transplant-free survival and lower adjusted hazard of liver-related events.
METHODS: This retrospective cohort study included patients with PSC followed at a tertiary referral center. VS was defined as moderate-to-severe interface hepatitis on liver histology combined with at least one of the following: alanine aminotransferase ≥5 × upper limit of normal (ULN), IgG ≥1.5 × ULN, or smooth muscle antibody titer ≥1:80.
RESULTS: Twenty-eight patients with VS and 274 non-VS patients were included. At diagnosis, VS patients were younger (median 20 vs. 30 years, p < 0.001), less frequently had inflammatory bowel disease (46.4% vs. 77.7%, p = 0.001), and more often presented with cirrhosis (25% vs. 8%, p = 0.010). Median follow-up was 9.9 years. Adjusted transplant-free survival was similar between groups (HR 0.33, 95% CI 0.11-1.00; p = 0.051). After adjustment, VS was associated with a lower risk of liver-related events (HR 0.27, 95% CI 0.09-0.80; p = 0.019).
CONCLUSIONS: Despite more frequent cirrhosis at diagnosis, patients with VS had comparable transplant-free survival and lower adjusted hazard of liver-related events.